Hamman-Rich syndrome natural history, complications and prognosis

	Hamman-Rich syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hamman-Rich syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hamman-Rich syndrome natural history, complications and prognosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hamman-Rich syndrome natural history, complications and prognosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hamman-Rich syndrome natural history, complications and prognosis
CDC on Hamman-Rich syndrome natural history, complications and prognosis
Hamman-Rich syndrome natural history, complications and prognosis in the news
Blogs on Hamman-Rich syndrome natural history, complications and prognosis
Directions to Hospitals Treating Hamman-Rich syndrome
Risk calculators and risk factors for Hamman-Rich syndrome natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chandrakala Yannam, MD [2]

Overview

If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].

OR

Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].

OR

Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.

The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
The symptoms of (disease name) typically develop ___ years after exposure to ___.
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].

Prognosis of acute interstitial pneumonitis is poor.^[2]^[3]
Most patients die because of acute respiratory failure or its complications.
Mortality rate is very high, more than half of the patients die within 2 months. Patients who survive the initial hospitalization die within six months of presentation of disease.
Recurrence of the disease and progression to chronic interstitial lung disease can occur among survivors.

↑ Matthay MA, Zimmerman GA (October 2005). "Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management". Am. J. Respir. Cell Mol. Biol. 33 (4): 319–27. doi:10.1165/rcmb.F305. PMC 2715340. PMID 16172252.
↑ Avnon LS, Pikovsky O, Sion-Vardy N, Almog Y (January 2009). "Acute interstitial pneumonia-Hamman-Rich syndrome: clinical characteristics and diagnostic and therapeutic considerations". Anesth. Analg. 108 (1): 232–7. doi:10.1213/ane.0b013e318188af7a. PMID 19095855.
↑ Parambil JG, Myers JL, Aubry MC, Ryu JH (July 2007). "Causes and prognosis of diffuse alveolar damage diagnosed on surgical lung biopsy". Chest. 132 (1): 50–7. doi:10.1378/chest.07-0104. PMID 17475632.